{
  "title": "Gene Therapy Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)",
  "slug": "gene-therapy-market",
  "industry": "Biotechnology & Genomics",
  "parent_industry": "Healthcare (Pharma, Medical Devices, Biotech)",
  "url": "https://www.mordorintelligence.com/industry-reports/gene-therapy-market",
  "scraped_at": "2026-09-17T17:44:52+07:00",
  "dataset_properties": [
    {
      "@type": "PropertyValue",
      "name": "Market Size (2026)",
      "value": 10.04,
      "unitText": "USD Billion"
    },
    {
      "@type": "PropertyValue",
      "name": "Market Size (2031)",
      "value": 25.89,
      "unitText": "USD Billion"
    },
    {
      "@type": "PropertyValue",
      "name": "Growth Rate (2026 - 2031)",
      "value": 20.86,
      "unitText": "PERCENT"
    },
    {
      "@type": "PropertyValue",
      "name": "Fastest Growing Market",
      "value": "Asia Pacific"
    },
    {
      "@type": "PropertyValue",
      "name": "Largest Market",
      "value": "North America"
    },
    {
      "@type": "PropertyValue",
      "name": "Market Concentration",
      "value": "Medium"
    }
  ],
  "faq": [
    {
      "@type": "Question",
      "name": "How fast is the gene therapy market expected to grow through 2031?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "The sector is forecast to expand at a 20.86% CAGR, taking revenue from USD 10.04 billion in 2026 to USD 25.89 billion by 2031."
      }
    },
    {
      "@type": "Question",
      "name": "Which therapy type is projected to grow the quickest?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Ex vivo therapies exhibit the fastest 21.97% CAGR outlook, driven by allogeneic CAR-T programs that eliminate the need for patient-specific manufacturing."
      }
    },
    {
      "@type": "Question",
      "name": "Why are payers beginning to cover high-priced gene therapies?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Outcomes-based contracts and real-world evidence demonstrating durable benefit have persuaded payers that one-time costs can offset lifelong disease management expenses."
      }
    },
    {
      "@type": "Question",
      "name": "Which region is poised for the highest growth through 2031?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "Asia-Pacific leads with a projected 28.78% CAGR as China, Japan, and South Korea align regulatory pathways and build manufacturing capacity."
      }
    },
    {
      "@type": "Question",
      "name": "What limits broader adoption despite regulatory momentum?",
      "acceptedAnswer": {
        "@type": "Answer",
        "text": "High manufacturing costs, long-term safety monitoring requirements, and viral-vector capacity constraints create cost and supply challenges that temper uptake."
      }
    }
  ],
  "images": [
    "images/gene-therapy-market-size-image-1776017403466.png",
    "images/gene-therapy-market_1658806947876_Gene_Therapy_Market_-_Keyplayers.png",
    "images/gene-therapy-market-Gene-Therapy-Market-Market-Share-by-Therapy-Type-2025-1767636531192.png",
    "images/gene-therapy-market-Gene-Therapy-Market-Market-Share-by-Indication-2025-1767636597045.png",
    "images/gene-therapy-market-Gene-Therapy-Market-Market-Share-by-End-User-2025-1767636679055.png",
    "images/gene-therapy-market-Gene-Therapy-Market-CAGR--Growth-Rate-by-Region-2026---2031-1767636705871.png",
    "images/gene-therapy-market-competitive-landscape-1749554246332.png",
    "images/market-snapshot.png",
    "images/pdf3.png",
    "images/Esomar-25.png",
    "images/GPTW-25-3xl.png",
    "images/gene-therapy-market-size-image-1776017403466.png"
  ],
  "sections_count": 14
}